Study of Apixaban for Treating Portal Vein Thrombosis More Than One Year After Laparoscopic Splenectomy and Azygoportal Disconnection

What this Trial Is About

Researchers are evaluating whether Apixaban is effective and safe for treating portal vein thrombosis that occurs more than one year after laparoscopic splenectomy and azygoportal disconnection. This study focuses on patients with cirrhosis and portal hypertension who develop this condition well after surgery. The goal is to understand how well Apixaban works in this specific situation to help guide future treatments. Participants who develop portal vein thrombosis more than 12 months after the surgery will take 2.5 mg of Apixaban orally twice daily. The effectiveness of the treatment will be assessed every three months using Doppler ultrasound or contrast-enhanced CT scans. If the treatment proves effective, patients will continue taking Apixaban long-term. Throughout the study, patients will undergo regular imaging to monitor the status of their portal vein thrombosis during treatment and follow-up. The main outcome measured is the proportion of patients who achieve complete recanalization of the portal vein after at least six months of treatment. Partial recanalization is also tracked as a secondary outcome. Participants will be observed for safety and treatment response until the study ends in 2027.

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD